About Us

STR Biotech Home

STR Biotech is a privately held, biopharmaceutical company focused on developing phagocytosis enhancer for the support treatment of cancer, autoimmune and other serious diseases.
The Company’s scientific advisors have significant expertise covering the development of biomedicine to regulation of GMP. At STR Biotech we currently selectively engage an innate immunity for treatment cachexia and neutropenia induced by anticancer drug.
Toloran4, developed through the company’s own highly active innate immunity development program, mediated TLR4 of innate immune cells and enhances phagocytosis (and endocytosis), and as a result, it can resolve inflammation in our body by rapidly removing surrounding DAMPs.
In addition to the opportunity in cancer induced neutropenia, Toloran4 will be also evaluated in Th2 biased disease like allergic rhinitis to asthma because phagocytosis can induce Th1 immune responses.